Last updated: 11/07/2018 13:51:26
An open two-part crossover study in healthy male volunteers to examine the effects of co-administration of Aludrox on the pharmacokinetics of BRL 29060 (paroxetine) after single oral dose of 30 mg BRL 29060
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An open two-part crossover study in healthy male volunteers to examine the effects of co-administration of Aludrox on the pharmacokinetics of BRL 29060 (paroxetine) after single oral dose of 30 mg BRL 29060
Trial description: An open two-part crossover study in healthy male volunteers to examine the effects of co-administration of Aludrox on the pharmacokinetics of BRL 29060 (paroxetine) after single oral dose of 30 mg BRL 29060
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Absorption of paroxetine under various dietary conditions and following antacid intake. Greb, W. H., Brett, M. A., Buscher, G., Dierdorf, H. D., von Schrader, H. W., Wolf, D., Mellows, G., and Zussman, B. D. Acta Psychiatr Scand Suppl 89; 350(99-101)
Medical condition
Mental Disorders
Product
paroxetine
Collaborators
Not applicable
Study date(s)
July 1983 to August 1983
Type
Not applicable
Phase
1
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1983-01-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website